Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Alzheimer's drug memantine tested on healthy brains – but study halted early

NCT ID NCT02288000

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Memantine

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2016

Finished

Dec 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-30 year old male non-smoker subjects * Subject without cognitive impairment or cognitive complaint (Moca\>26, Mac Nair scale\<15) * Subject without history of brain disease (severe brain trauma, stroke, cerebral tumor,…) * Subject without major medical or surgical history * Subject without current chronic disease * Subject without current cerebral disease * Subject without vascular or metabolic risk factor * Subject without history or current mental disease or addiction (MINI) * Subject without lesion on MRI * Subject without abnormal electrical activities on EEG * Subject without use of chronic treatment or psychotropic drugs or substances * French speaker subject and able to understand the test instructions Exclusion Criteria: * Subject with dementia or cognitive decline identified by Moca \< 26 * Subject with vascular or metabolic risk factor * Subject with history or current mental disease or addiction * Subject with family history of young-onset dementia * Subject with family history of chronic or severe neurological or mental disease (first degree relatives) * Subject receiving a chronic treatment * Subject with claustrophobia or contra-indication to MRI * Subject unable to understand the test instructions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Battery

Contacts and locations

Locations

  • CHRU de Lille/ Centre d'investigation Clinique

    Lille, 59037, France

  • CIC Marseille

    Marseille, France

  • CIC Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.